From GlobeNewswire: 2025-04-17 07:38:00

Clearmind Medicine Inc. announced a Notice of Allowance for a US patent related to its MEAI treatment for binge behavior. This strengthens their intellectual property portfolio and potential for transformative outcomes for patients. The company focuses on developing psychedelic-derived therapeutics for underserved health problems, with 31 granted patents and plans for more. Shares of Clearmind are listed on Nasdaq as “CMND” and the Frankfurt Stock Exchange as “CWY0.” For more information, visit their website or contact Investor Relations at [email protected] or General Inquiries at [email protected].



Read more at GlobeNewswire: Clearmind Medicine Receives Notice of Allowance for United